Just out from the NeuroCyto team: the ultrastructure of actin rings revealed
Our work on the ultrastructure of the periodic actin/spectrin scaffold along axons is out in Nature Communications.
The PFNT Facility is a coherent set of exploration tools in neurobiology allowing research at the molecular, cellular and integrated levels.
In the context of the Euronanomed projects for Action on Nanomedicine under Horizon 2020, a Symposium will be held at the Luminy campus in Marseille on March 8, 2019. Dr. Khrestchatisky will give a talk titled "Molecular vectors for drug delivery into the brain and tumors".
For more information, please visit the symposium website or download the pdf version of the program.
In an interview published by "La Provence" on November 30, 2018 Yvon Bertrand, President of Aix-Marseille University, explains that AMU is very proud of its contribution to the field of Artificial Intelligence but also to the development of companies such as "First Light Imaging", VECT-HORUS or Innate-Pharma. They are real success stories from public research.
INP Cytoskeleton and Neurophysiopathology team, together with several leading groups in tau biology, has participated in a joint review of the field that just came out in Acta Neuropathologica Communications. This review summarizes the recent breakthroughs in deciphering the molecular structures, both physiological and pathological, of the elusive protein tau.
Read online (open access) : https://link.springer.com/article/10.1186/s40478-019-0682-x
Title : The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?
The last work of team 9 "Tau regulates the microtubule-dependent migration of glioblastoma cells via Rho-ROCK signaling pathway" is now published in J. cell. Science. This work identifies for the first time the role and mechanisms implicating the tau protein in the invasion processes of glioblastomas, very aggressive brain tumors. This work highlights the role of the Tau protein as a common target between cancers and neurodegeneration.
Professor of Biophysics and Biomathematics at the Faculty of Pharmacy of Marseille, Hervé Kovacic is elected for a six-year term. Section CNU 85 manages the qualifications, promotions and bonuses of teacher-researchers specializing in physicochemical sciences and applied engineering in health. Doctor Pascale Barbier, also from team 9 of INP has been nominated as a member of the same CNU section.
Jean-Michel Paumier, former PhD student in Team 1 (Neural Plasticity and Degeneration), has successfuly defended his thesis on Wednesday the 05th of December 2018. After few hours of a nice presentation followed by many questions, the examining board congratulated Jean-Michel for his good work and granted him the diploma of doctor in Neuroscience.
On December 6 and 7, 2018, Neuroschool PhD Days took place. In this edition entitled "Through the looking glass: beyond our reality", second-year neuroscience PhD students were invited to present their work.
It is in this context that the 3 PhD students of the INP took part: Laurie Arnaud, Audrey Jacq and Dominika Pilat.
Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The goal of this collaboration is to use Vect-Horus’ proprietary technology to transport various Janssen monoclonal antibodies to the brain for the treatment of neurodegenerative diseases. This deal was facilitated by Johnson & Johnson Innovation Limited.
Our work on the ultrastructure of the periodic actin/spectrin scaffold along axons is out in Nature Communications.
In a large cohort of 911 high-grade IDH-mutant gliomas from the French national POLA network, we investigated the prognostic value of the CDKN2A gene homozygous deletion as well as WHO grading criteria (mitoses, microvascular proliferation, and necrosis).
We showed that:
- CDKN2A homozygous deletion characterizes diffuse malignant IDH-mutant gliomas with worst outcome.
- Microvascular proliferation stratifies IDH-mutant gliomas lacking CDKN2A homozygous deletion.
Michel KHRESTCHATISKY, Director of the UMR7051 Institute of Neurophysiopathology at Aix-Marseille University / CNRS and co-founder of VECT-HORUS was invited at the third edition of “Translational neuroscience Day: challenges and opportunities” co-organized by DHUNE and NeurATRIS and hosted by BioFIT on December 10, 2019 (https://www.biofit-event.com/translational-neuroscience).
In this paper, Daniel Bertin evaluated the immunological follow-up of patients suffering from chronic inflammatory diseases and receiving anti-TNF biotherapy. Three commercial ELISA assays for monitoring soluble through levels of infliximab and anti-infliximab antibodies in serum showed a good global correlation of results. However, some quantitative discrepancies could change clinical decision. As a consequence, Daniel Bertin recommended to keep the same kit to perform a longitudinal follow-up of patients.
Aurélie Tchoghandjian-Auphan, CRCN CNRS from the GlioME team, in the Insitute of NeuroPhysiopathology, UMR CNRS 7051, was recently granted by ARC fondation for her project "Effects of Smac mimetics treatment on glioblastomas immune response".
Subsequently she was interviewed by :
- France 3 (JT 19/20 PACA diffusion du 15/11: 7'09 à 9'45) ;
- Provence Azur (18/11/2019) ;
- 20 Minutes Marseille (18/11/2019)
- La Provence
Our data show that VEGF blockade leads to an increased recruitment of monocytes and to an adjustment of dendritic cell subsets’ profiles, differing in their ability to induce an adaptive immune response. Altogether, they provide important new insights into the effects of Bevacizumab at the cellular level and into the spatio-temporal evolution of intra-tumoral innate immune cell densities.